Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Drug Safety Oversight Board Looks To Promote Its Value

Executive Summary

FDA's Drug Safety Oversight Board is trying to promote its value to the medical and regulatory communities by highlighting its role in addressing postmarketing safety issues

You may also be interested in...



New Nimodipine Formulation Aimed At Reducing Fatal Medication Errors

Nymalize, an oral formulation of brain hemorrhage treatment nimodipine, aims to minimize serious risks associated with incorrect administration of older forms of the drug.

Behind Closed Doors: FDA Drug Safety Board Will Keep Its Decisions Private

The pharmaceutical industry and other FDA stakeholders should not hold their breath waiting for more details about the agency's Drug Safety Oversight Board recommendations or the extent of internal debate and disagreement at its monthly non-public meetings

Behind Closed Doors: FDA Drug Safety Board Will Keep Its Decisions Private

The pharmaceutical industry and other FDA stakeholders should not hold their breath waiting for more details about the agency's Drug Safety Oversight Board recommendations or the extent of internal debate and disagreement at its monthly non-public meetings

Related Content

Topics

UsernamePublicRestriction

Register

PS052530

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel